Biogen will advance anti-tau ASO to phase three despite missing primary endpoint in phase two Alzheimer's trial.
“Biogen is gonna show full data for their anti tau ASO, for the treatment of Alzheimer's. The study missed its primary endpoint, but Biogen is moving into phase three.”
→ Read the source episode
Our resolution criterion
disputableBiogen formally initiates phase three trial(s) for anti-tau ASO in Alzheimer's disease
More from Biotech Hangout
Tarsus Pharmaceuticals' Alkias phase three Northstar study for gilderretinol will report data in H2 2029.
Ten X will meet with EMA to explore enriched patient populations for HFpEF drug following failed phase three.
Brian Skorney predicts Lilly's Lp(a) CVOT data may read out in 2029.
Paul Matisse reports Biohaven's KV7 epilepsy drug is on partial clinical hold with phase 3 data coming soon.
Eric Schmidt predicts the HARMONY three study for evanesquimab will read out positively in 6-9 months.
Daphne Zohar predicts Heidi Overton's FDA commissioner confirmation hearings will occur after the Senate summer recess.
Summaries are ours; the quote is a verbatim transcript excerpt. Our resolution criteria are editorial and disputable. How this works.